The results indicated that serum KRAS exhibits a diagnostic accuracy in distinguishing between early and late stage of ovarian cancer (AUC = 0.8, 95% CI = 0.682 to 0.949, P = 0.0002), demonstrating a sensitivity of 87.86% and specificity of 80% at a cutoff > 149.7 ng/ml (Fig. 5c). Here, KRAS is linked to ovarian cancer.